Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients
Saad Usmani, MD, MBA, FACP
Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)
Brian Primeaux, PharmD, BCOP
Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
Jonathan Riess, MD, MS
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Mariana Chavez-McGregor, MD, MSc, FASCO
